Share this article
Share this article
CALGARY, AB, April 21, 2021 /PRNewswire/ - Canadian Pacific Railway Limited (TSX: CP) (NYSE: CP) today announced first-quarter operating results, including revenues of $1.96 billion, an operating ratio ( OR ) of 60.2 percent, adjusted OR of 58.5 percent, diluted earnings per share ( EPS ) of $4.50 and adjusted diluted EPS of $4.48. The strong demand environment, particularly across bulk, merchandise and domestic intermodal, coupled with our commitment to the foundations of precision scheduled railroading enabled our success in the first quarter, said Keith Creel, CP President and Chief Executive Officer. The CP family demonstrated resiliency through winter and delivered a record March. Our 12,000-strong team continues to deliver, no matter the obstacles, and I am extremely proud of their efforts.
Orosur Mining Inc Announces Third Quarter Results for 2020/21
LONDON, UK / ACCESSWIRE / April 14, 2021 /
Orosur Mining Inc. ( Orosur or the Company ) (TSX:OMI)(AIM:OMI), a South American-focused gold developer and explorer, is pleased to announce the results for the third quarter ended February 28, 2021 ( Q3 21 or the Quarter ). All dollar figures are stated in US$ unless otherwise noted. The unaudited condensed financial statements of the Company for the quarter ended February 28, 2021 and the related management s discussion and analysis have been filed and are available for review on the SEDAR website at www.sedar.com. They are also available on the Company s website at www.orosur.ca.
/CNW/ - Aphria Inc. ("Aphria," "we," or the "Company") (TSX: APHA) (NASDAQ: APHA), a leading global cannabis-lifestyle consumer packaged goods company.
Avidian Gold : Consolidated Financial Statements for the three and six months ending December 31, 2020 and 2019 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Edesa Biotech Reports Fiscal First Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / February 16, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2020 and provided an update on its business.
Earlier this month, the company announced that it has been awarded a C$14 million reimbursement grant from the Canadian government. The funds will support the Phase 2 portion of an ongoing Phase 2/Phase 3 clinical study of Edesa s investigational drug, EB05, as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Should the antibody treatment demonstrate promising results at the Phase 2 readout, the company plans to continue with a pivotal Phase 3 study and enter negotiations for additional government funding. Last mont